微信上能卖药吗?网售药品监管范围扩大到移动互联网

2018-02-11 卜艳 健康点healthpoint

网售药品的监管范围也从PC端扩大到移动互联网平台,其中包括微博、微信。

看来,关于网售药品究竟该如何监管,着实令CFDA很伤脑筋。

距离去年11月份CFDA发布网络药品经营监督管理办法(征求意见稿)》不到3个月时间,新一版本的网售药品监管征求意见稿公之于众。

2月9日,CFDA发布的《药品网络销售监督管理办法(征求意见稿)》(以下简称《办法》)发布。同时,这一《办法》还在国务院法制办向社会各界公开征求意见。

健康点对比了前后两次出台的征求意见稿内容,“禁止展示、销售处方药”没有丝毫商量的余地;网售药品必须坚持线上线下一致这一原则:线上销售的药品必须经过药监部门许可,才能在线上销售,线上销售药品的企业必须取得药品经营许可证,才能在线上开展药品交易活动。

但《办法》有三大变化值得关注。

三大变化

首先,《办法》名称从“药品网络经营”改成“网络药品销售”,后者所包含的服务主体范围要更大。此前“药品网络经营”更多是指互联网PC端的药品交易,而“网络药品销售”则扩大到移动互联网,其中包括微博、微信这样的社交平台。

国务院法制办关于《网络药品销售监督管理办法(征求意见稿)》的起草说明提到:近年来,医药健康类移动互联网应用程序(手机APP)应运而生,微博、微信涉及药品交易增多,而现行的互联网药品监管法律法规对其监管仍处于无章可循的境地。因此,《办法》将适用范围由互联网拓展至移动互联网,将通过移动互联网开展的药品销售行为和第三方交易服务也纳入调整范畴。

移动互联网纳入网售药品监管范围在去年11月份发布的征求意见稿中也有提及,但并未做强调。

其次,《办法》第二条则由原先的“国家食品药品监督管理总局主管全国网络药品经营监督管理工作”修改为“国家食品药品监督管理总局指导全国药品网络销售监督管理工作”,并增加“省级食品药品监督管理部门负责药品网络交易服务的监督管理”。从“主管”到“指导”的背后,是国家食品药品监督管理总局或将网售药品的主要监管权力下放到省级食药监部门。

此外,《办法》起草说明提出,可以放开的有条件的放开,比如通过第三方平台向个人消费者售药;不宜放开的暂时仍是禁止,比如禁止向个人消费者网售处方药,禁止单体药店网售药品。看来,禁止网售处方药几乎已是板上钉钉的事情。

2016年,天猫医药馆、1号药网、八百方这三家拿到网售药品第三方平台试点资质的平台暂停销售药品,由此也给行业发展蒙上一层阴影。而此次《办法》或将会让网售药品第三方平台迎来新转机。

建立统一监测系统

2月2日,CFDA在其官网上挂出一则政府采购项目招标公告——《总局南方医药经济研究所网络药品信息和交易监测系统建设项目成交公告》。

对于该项目的招标原因,在公布的《网络药品信息和交易监测系统项目磋商文件》(以下简称:磋商文件)中提到,因为“网络药品交易具有隐蔽性、虚拟性和跨地域性等特点,传统的监督检查的手段已经难以适应当前监管新形势的需要,鉴于此,迫切需要展看全网统一监测工作,运用信息化手段提升监管效率,保障药品质量安全。”

项目目的是希望“利用信息化技术和手段完成对涉嫌违法违规的药品信息和交易网站的全网搜索,进一步加强网络药品信息发布和售药行为的监管。”

健康点了解到,此次南方医药经济研究所进行网络药品信息和交易监测并不只针对网售处方药,还包括海外药品代购、未获得国药准字批准的药品销售等非法交易行为。监测的网络药品销售平台包括:天猫医药馆、京东医药馆、360好药、药房网商城、八百方。

《磋商文件》中还提到,项目开展后,先将PC端网站纳入监测范围,随后逐步将微博、微信等移动社交媒体及App工具纳入监测范围。

但对于监测后发现的违规违法行为,目前相应的处罚力度有限。比如针对违法销售药品,处罚方式为没收违法销售的药品和违法所得,并处违法销售的药品货值金额2倍以上5倍以下的罚款;“违规通过网络发布处方药信息、未及时按规定处理存质量或安全隐患药品”等行为罚款则在3万元以下。

显然,这样的处罚力度很难对相应的违规平台有震慑力。另一方面,上有政策下有对策,也有不少业内人士提出这一监测平台实际意义有限。但不可否认,CFDA对于网售药品的监管方向总体趋于严格。

按照《办法》规定,此次征求意见稿截止时间为3月12日。还有一个月左右的时间,这一《办法》最终能否顺利出台,何时出台,目前来看还是未知数。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1672230, encodeId=991f16e223020, content=<a href='/topic/show?id=84848e4625a' target=_blank style='color:#2F92EE;'>#药品监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87462, encryptionId=84848e4625a, topicName=药品监管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b3026899023, createdName=yzh408, createdTime=Mon Aug 13 23:03:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274138, encodeId=b6b712e4138ce, content=<a href='/topic/show?id=04fd241222d' target=_blank style='color:#2F92EE;'>#互联网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24122, encryptionId=04fd241222d, topicName=互联网)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Tue Feb 13 00:03:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371517, encodeId=a0e713e1517e0, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Tue Feb 13 00:03:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589088, encodeId=4f2d158908870, content=<a href='/topic/show?id=753950491ed' target=_blank style='color:#2F92EE;'>#微信#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50491, encryptionId=753950491ed, topicName=微信)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e9417676193, createdName=smlt2014, createdTime=Tue Feb 13 00:03:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287076, encodeId=e55e28e076bb, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Feb 11 11:40:18 CST 2018, time=2018-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287036, encodeId=d4ff28e036f3, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfDEeydJz0GlP8O0ngrUX6AYCXFic0XDOOAyeQicIqnOd4TrWSwiagJrsFNYuWC1Uc6iavbS1hWt9xtZAhAqLGHqZyl/0, createdBy=42891977006, createdName=1e17414fm02(暂无匿称), createdTime=Sun Feb 11 09:06:37 CST 2018, time=2018-02-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1672230, encodeId=991f16e223020, content=<a href='/topic/show?id=84848e4625a' target=_blank style='color:#2F92EE;'>#药品监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87462, encryptionId=84848e4625a, topicName=药品监管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b3026899023, createdName=yzh408, createdTime=Mon Aug 13 23:03:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274138, encodeId=b6b712e4138ce, content=<a href='/topic/show?id=04fd241222d' target=_blank style='color:#2F92EE;'>#互联网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24122, encryptionId=04fd241222d, topicName=互联网)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Tue Feb 13 00:03:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371517, encodeId=a0e713e1517e0, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Tue Feb 13 00:03:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589088, encodeId=4f2d158908870, content=<a href='/topic/show?id=753950491ed' target=_blank style='color:#2F92EE;'>#微信#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50491, encryptionId=753950491ed, topicName=微信)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e9417676193, createdName=smlt2014, createdTime=Tue Feb 13 00:03:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287076, encodeId=e55e28e076bb, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Feb 11 11:40:18 CST 2018, time=2018-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287036, encodeId=d4ff28e036f3, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfDEeydJz0GlP8O0ngrUX6AYCXFic0XDOOAyeQicIqnOd4TrWSwiagJrsFNYuWC1Uc6iavbS1hWt9xtZAhAqLGHqZyl/0, createdBy=42891977006, createdName=1e17414fm02(暂无匿称), createdTime=Sun Feb 11 09:06:37 CST 2018, time=2018-02-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1672230, encodeId=991f16e223020, content=<a href='/topic/show?id=84848e4625a' target=_blank style='color:#2F92EE;'>#药品监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87462, encryptionId=84848e4625a, topicName=药品监管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b3026899023, createdName=yzh408, createdTime=Mon Aug 13 23:03:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274138, encodeId=b6b712e4138ce, content=<a href='/topic/show?id=04fd241222d' target=_blank style='color:#2F92EE;'>#互联网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24122, encryptionId=04fd241222d, topicName=互联网)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Tue Feb 13 00:03:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371517, encodeId=a0e713e1517e0, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Tue Feb 13 00:03:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589088, encodeId=4f2d158908870, content=<a href='/topic/show?id=753950491ed' target=_blank style='color:#2F92EE;'>#微信#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50491, encryptionId=753950491ed, topicName=微信)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e9417676193, createdName=smlt2014, createdTime=Tue Feb 13 00:03:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287076, encodeId=e55e28e076bb, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Feb 11 11:40:18 CST 2018, time=2018-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287036, encodeId=d4ff28e036f3, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfDEeydJz0GlP8O0ngrUX6AYCXFic0XDOOAyeQicIqnOd4TrWSwiagJrsFNYuWC1Uc6iavbS1hWt9xtZAhAqLGHqZyl/0, createdBy=42891977006, createdName=1e17414fm02(暂无匿称), createdTime=Sun Feb 11 09:06:37 CST 2018, time=2018-02-11, status=1, ipAttribution=)]
    2018-02-13 wwzzly
  4. [GetPortalCommentsPageByObjectIdResponse(id=1672230, encodeId=991f16e223020, content=<a href='/topic/show?id=84848e4625a' target=_blank style='color:#2F92EE;'>#药品监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87462, encryptionId=84848e4625a, topicName=药品监管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b3026899023, createdName=yzh408, createdTime=Mon Aug 13 23:03:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274138, encodeId=b6b712e4138ce, content=<a href='/topic/show?id=04fd241222d' target=_blank style='color:#2F92EE;'>#互联网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24122, encryptionId=04fd241222d, topicName=互联网)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Tue Feb 13 00:03:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371517, encodeId=a0e713e1517e0, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Tue Feb 13 00:03:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589088, encodeId=4f2d158908870, content=<a href='/topic/show?id=753950491ed' target=_blank style='color:#2F92EE;'>#微信#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50491, encryptionId=753950491ed, topicName=微信)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e9417676193, createdName=smlt2014, createdTime=Tue Feb 13 00:03:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287076, encodeId=e55e28e076bb, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Feb 11 11:40:18 CST 2018, time=2018-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287036, encodeId=d4ff28e036f3, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfDEeydJz0GlP8O0ngrUX6AYCXFic0XDOOAyeQicIqnOd4TrWSwiagJrsFNYuWC1Uc6iavbS1hWt9xtZAhAqLGHqZyl/0, createdBy=42891977006, createdName=1e17414fm02(暂无匿称), createdTime=Sun Feb 11 09:06:37 CST 2018, time=2018-02-11, status=1, ipAttribution=)]
    2018-02-13 smlt2014
  5. [GetPortalCommentsPageByObjectIdResponse(id=1672230, encodeId=991f16e223020, content=<a href='/topic/show?id=84848e4625a' target=_blank style='color:#2F92EE;'>#药品监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87462, encryptionId=84848e4625a, topicName=药品监管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b3026899023, createdName=yzh408, createdTime=Mon Aug 13 23:03:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274138, encodeId=b6b712e4138ce, content=<a href='/topic/show?id=04fd241222d' target=_blank style='color:#2F92EE;'>#互联网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24122, encryptionId=04fd241222d, topicName=互联网)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Tue Feb 13 00:03:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371517, encodeId=a0e713e1517e0, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Tue Feb 13 00:03:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589088, encodeId=4f2d158908870, content=<a href='/topic/show?id=753950491ed' target=_blank style='color:#2F92EE;'>#微信#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50491, encryptionId=753950491ed, topicName=微信)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e9417676193, createdName=smlt2014, createdTime=Tue Feb 13 00:03:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287076, encodeId=e55e28e076bb, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Feb 11 11:40:18 CST 2018, time=2018-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287036, encodeId=d4ff28e036f3, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfDEeydJz0GlP8O0ngrUX6AYCXFic0XDOOAyeQicIqnOd4TrWSwiagJrsFNYuWC1Uc6iavbS1hWt9xtZAhAqLGHqZyl/0, createdBy=42891977006, createdName=1e17414fm02(暂无匿称), createdTime=Sun Feb 11 09:06:37 CST 2018, time=2018-02-11, status=1, ipAttribution=)]
    2018-02-11 1e145228m78(暂无匿称)

    学习了.谢谢作者分享!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1672230, encodeId=991f16e223020, content=<a href='/topic/show?id=84848e4625a' target=_blank style='color:#2F92EE;'>#药品监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87462, encryptionId=84848e4625a, topicName=药品监管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b3026899023, createdName=yzh408, createdTime=Mon Aug 13 23:03:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274138, encodeId=b6b712e4138ce, content=<a href='/topic/show?id=04fd241222d' target=_blank style='color:#2F92EE;'>#互联网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24122, encryptionId=04fd241222d, topicName=互联网)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Tue Feb 13 00:03:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371517, encodeId=a0e713e1517e0, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Tue Feb 13 00:03:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589088, encodeId=4f2d158908870, content=<a href='/topic/show?id=753950491ed' target=_blank style='color:#2F92EE;'>#微信#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50491, encryptionId=753950491ed, topicName=微信)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e9417676193, createdName=smlt2014, createdTime=Tue Feb 13 00:03:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287076, encodeId=e55e28e076bb, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Feb 11 11:40:18 CST 2018, time=2018-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287036, encodeId=d4ff28e036f3, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfDEeydJz0GlP8O0ngrUX6AYCXFic0XDOOAyeQicIqnOd4TrWSwiagJrsFNYuWC1Uc6iavbS1hWt9xtZAhAqLGHqZyl/0, createdBy=42891977006, createdName=1e17414fm02(暂无匿称), createdTime=Sun Feb 11 09:06:37 CST 2018, time=2018-02-11, status=1, ipAttribution=)]
    2018-02-11 1e17414fm02(暂无匿称)

    学习

    0